Cyclo (RLsKDK) (TFA)

Cyclo (RLsKDK) (TFA) (BK-1361 (TFA) ) is a specific inhibitor of metalloproteinase ADAM8 with an IC50 value of 182 nM. cyclo (RLsKDK) (TFA) has potential applications in inflammatory diseases and cancer[1].

Product Specifications

Product Name Alternative

BK-1361 (TFA)

UNSPSC

12352209

Target

MMP

Type

Peptides

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/cyclo-rlskdk-tfa.html

Purity

99.66

Solubility

H2O : 100 mg/mL (ultrasonic)

Smiles

N=C(N)NCCC[C@@H](C(N[C@H](C(N[C@@H](C(N[C@H]1CCCCN)=O)CO)=O)CC(C)C)=O)NC([C@@H](NC([C@@H](NC1=O)CC(O)=O)=O)CCCCN)=O.O=C(O)C(F)(F)F

Molecular Formula

C33H58F3N11O11

Molecular Weight

841.88

References & Citations

[1]Yim V, et al. Synthesis and biological evaluation of analogues of the potent ADAM8 inhibitor cyclo (RLsKDK) for the treatment of inflammatory diseases and cancer metastasis. Bioorg Med Chem. 2016 Sep 15;24 (18) :4032-4037.|[2]Schlomann U, et al. ADAM8 as a drug target in pancreatic cancer. Nat Commun. 2015 Jan 28;6:6175.